SBSamira Kumar Behera

Samira Kumar Behera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samira Kumar Behera has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association of TMPRSS6 Gene Polymorphism (rs855791) with Iron Status and Erythrocyte Indices in a Pediatric Cohort Evaluated for Anemia

    by Prasanta Purohit, Anuva Mishra, Chinmaya Mund, Sunil Sahu, Samira Kumar Behera, Rasmita Kumari Padhy, Nirupama Devi

  • Open Access

    Molecular analysis of BCR-ABL1 fusion transcripts in acute leukemia patients in Southern Odisha, India

    by Sheetal Sabat, Aparupa Naik, Prasanta Purohit, Snehal Bholo, Chinmayee Parida, Manoj Kumar Patro, Samira Kumar Behera

    Introduction and aim. The occurrence of BCR-ABL1 fusion transcript in acute-leukemia cases are limited and is characterized with various subtypes. This study was based on investigation of the BCR-ABL1 fusion transcript in acute-leukemia cases in a tertiary care hospital. Material and methods. This cross-sectional study was carried out in suspected cases of acute leukemia. Cases were analyzed for complete blood counts, peripheral smear, bone marrow and flow-cytometry for the diagnosis of acute-leukemia. Additionally, diagnosed cases were investigated for BCR-ABL1 fusion transcript by PCR amplification using reverse transcriptase enzyme followed by documentation. Results. Approximately 55 acute leukemia cases included, diagnosed by flow cytometric analysis. Analysis of the BCR-ABL1 fusion-transcript in 55 cases showed its occurrence in only 2 cases, where one case with the B-ALL was characterized with e1a2 subtype and a other case with AML was characterized with the e13a2 subtype. Conclusion. The BCR-ABL1 fusion transcript in acute-leukemia cases was found in 3.64% (2/55) of cases. The diagnosis of BCR-ABL1 fusion transcript in acute-leukemia cases is important for its poor prognosis, as well as calls for the use of ABL tyrosine kinase inhibitors. The diagnosis of BCR-ABL1 fusion-transcript in acute leukemia cases in a tertiary health care facility will be helpful for better treatment of patients in the study area.

  • Open Access

    Evaluation of a point-of-care rapid diagnostic test kit (SICKLECHECK) for screening of sickle cell diseases

    by Prasanta Purohit, Chinmayee Parida, Tapan Kumar Martha, Snehal Bholo, Aparupa Naik, Samira Kumar Behera

    Sickle cell diseases (SCD) are the most common genetic disorders with significant morbidity and mortality worldwide, including in India. The high prevalence of this disorder in many geographical regions calls for the use of a point-of-care rapid diagnostic test (RDT) for early screening and management of the diagnosed cases to reduce the allied clinical severity. In view of this, the present study was undertaken for the validation of a point-of-care RDT kit (SICKLECHECKTM) for the screening of SCD. This validation and diagnostic accuracy study was conducted among the cases advised for screening of SCD. For validation, all the recruited cases were investigated for both the SICKLECHECKTM RDT kit and HPLC (Variant-II) considering HPLC as a gold standard. A total of 400 cases were screened for both tests. For the presence and absence of sickle cell hemoglobin in the samples, SICKLECHECKTM RDT kit results showed a sensitivity and specificity of 99.39% and 98.73% respectively with references to HPLC findings. For the detection of the ‘AS’ pattern, the SICKLECHECKTM RDT kit has shown a sensitivity and specificity of 99.07% and 98.81% respectively. For the detection of the ‘SS’ pattern, the SICKLECHECKTM RDT kit has shown a sensitivity and specificity of 97.92% and 100.0% respectively. Cases with β thalassemia trait, hemoglobin E trait, hemoglobin Lepore trait and trait for hereditary-persistence-of-fetal-hemoglobin (high HbF %) diagnosed in HPLC were resulted with ‘AA’ pattern in SICKLECHECKTM RDT kit. The high sensitivity and specificity of the SICKLECHECKTM RDT kit insist on its use as a point-of-care screening tool for SCD especially where there is a lack of laboratory facilities as well as in hospital-based set-up requiring immediate diagnosis and management of SCD. However, for further confirmation, the samples should be analyzed with other gold standard techniques like HPLC.


  • Utility of Low-cost Paper Based Haemoglobin Solubility Test for the Rapid Diagnosis of Sickle Cell Disease

    by Minakshi Swain, Prasanta Purohit, Samira Kumar Behera

    In this study, we describe and compare a simple, rapid, low cost, point-of-care diagnostic paper-based test for screening of sickle cell disease, which is based on principle of haemoglobin solubility. This observational study was carried out in 384 cases advised for screening of haemoglobin disorders by HPLC. All the cases were subjected to both HPLC and modified sickle cell paper solubility test simultaneously. The results of both the test were compared accordingly. Further to check the minimum level of HbS that can be identified by paper solubility test, a sample dilution method was used and analyzed. Out of 384 cases, 131 cases were found to have an HbS window in the HPLC report and rest 263 cases were found to have either normal or other haemoglobin variants. The paper solubility test also showed the similar results with 100% of sensitivity and specificity. Further, a > 5% of HbS can be traced and identified by paper solubility test. The paper-based haemoglobin solubility test was seen to be capable of distinguishing sickle cell patients from non sickle cell blood samples with a high degree of accuracy. It is a very rapid test that can be performed by a person with minimal training at community level (field study). The paper based Hb Solubility test is a low cost, easy, rapid, accurate, point of care and reproducible screening test for sickle cell patients.

  • Open Access

    Transition from Morphocytochemical Diagnosis to Immunophenotypic Diagnosis of Acute Leukemia: A Flow Cytometry Experience from Southern Odisha

    by Chaitali Patnaik, Prasanta Purohit, Samira K. Behera, Swayamprabha Pradhan

    Background: In today’s generation of targeted therapy, traditional reporting of acute leukemia by morphology using the FAB system of classification has limited uses due to a lack of standardization and use in risk stratification. Immunophenotyping by flow cytometry has gained popularity due to its influence on the treatment and prognosis of the disease. The present study evaluates the judicious application of flow cytometry as an adjunct to morphocytochemical assessment in all newly diagnosed cases of acute leukemia in Southern Odisha. Materials and Methods: A total of 61 cases were subjected to complete blood count analysis, peripheral smear examination, bone marrow study, cytochemistry, and those suspected of leukemia underwent flow cytometry analysis using BD FACS CANTO II as per manufacturer’s instructions. Results: Out of 61 cases of acute leukemia diagnosed, 35 were acute lymphoblastic leukemia, and 24 were acute myeloid leukemia. There was 96.7% correlation between diagnosis by cytomorphology and flow cytometry. Seven cases showed aberrant expression of various antigens. Two cases of acute leukemia on cytomorphology were diagnosed as hematogones and the other as reactive lymphocytosis on flow cytometry. Conclusion: Although morphologic FAB diagnosis is still widely used to classify acute leukemia, flow cytometry has more specificity and should be used as an adjunct to morphology. Along with subclassification of leukemia, flow cytometry can also detect the possibility of an associated genetic abnormality.